Table 2. Crossclassification of patients by the European League Against Rheumatism (EULAR) response criteria based on the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte sedimentation rate (ESR) scales at 6 months (AIM (Abatacept in Inadequate responders to Methotrexate) and ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trials, both treatment groups combined*).

		DAS28 (CRP)
		Good responder n (%)	Moderate responder n (%)	Non-responder n (%)
DAS28 (ESR)	Good responder n (%)	108 (14.4)†	12 (1.6)	1 (0.1)
	Moderate responder n (%)	56 (7.4)	352 (46.8)†	24 (3.2)
	Non-responder n (%)	0 (0)	39 (5.2)	160 (21.3)†

*n = 752, based on all randomised and treated patients with CRP and ESR measurements available; †indicates agreement between EULAR response criteria based on DAS28 (ESR) and DAS28 (CRP).